Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 3/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | MME | P08473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA2 | P00918 | 1/20 | 0.36 |
| ▸ | CA3 | P07451 | 1/20 | 0.36 |
| ▸ | CA4 | P22748 | 1/20 | 0.36 |
| ▸ | CA6 | P23280 | 1/20 | 0.36 |
| ▸ | CA5A | P35218 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA13 | Q8N1Q1 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | FYN | P06241 | 1/20 | 0.33 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6869302 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL31030093 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL2322722 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL16223981 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL31030092 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL2322732 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL22129282 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL22426199 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL22231243 | 1.00 | BRD4 (0.38) | BRD4MAPTMMELMNACA12 | |
| SCHEMBL5012986 | 0.91 | ACE (0.43) | BRD4MAPTMMEACETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4282971-A1 | AN IMPROVED PROCESS FOR THE PREPARATION OF (R )-4-PROPYL PYRROLIDINE-2-ONE, A KEY INTERMEDIATE FOR SYNTHESIS OF BRIVARACETAM | Divi's Laboratories Limited (IN) | 2023-11-29 | — | — | EP | disclosed |
| EP-3812371-A1 | A PROCESS FOR PREPARING BRIVARACETAM | Divi's Laboratories Limited (IN) | 2021-04-28 | — | — | EP | disclosed |
| US-10781170-B1 | Process for preparing Brivaracetam | DIVI'S LABORATORIES LTD. (IN) | 2020-09-22 | — | — | US | disclosed |
| US-8338621-B2 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB S.A. (BE) | 2012-12-25 | — | — | US | disclosed |
| EP-1806339-B1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB PHARMA SA (BE) | 2011-08-17 | — | — | EP | disclosed |
| US-7563912-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2009-07-21 | — | — | US | disclosed |
| EP-1419144-B1 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB PHARMA SA (BE) | 2008-10-08 | — | — | EP | disclosed |
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | UCB S.A. (BE) | 2008-01-10 | — | — | US | disclosed |
| EP-1806339-A1 | Process for the preparation of 2-oxo-1-pyrrolidine derivatives | UCB, S.A. (BE) | 2007-07-11 | — | — | EP | disclosed |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | ATES CELAL | 2007-06-21 | — | — | US | disclosed |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2006-11-16 | — | — | US | disclosed |
| US-7122682-B2 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB, S.A. (BE) | 2006-10-17 | — | — | US | disclosed |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | UCB PHARMA, S.A. (BE) | 2004-10-14 | — | — | US | disclosed |
| EP-1419144-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2004-05-19 | — | — | EP | disclosed |
| WO-2003014080-A2 | OXOPYRROLIDINE COMPOUNDS, PREPARATION OF SAID COMPOUNDS AND THEIR USE IN THE MANUFACTURING OF LEVETIRACETAM AND ANALOGUES | UCB, S.A. (BE) | 2003-02-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080009638-A1 | PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES | CYP2F1, CYP3A5, SULT1E1 | BRD4 631/4885MAPT 1791/4885MME 4138/4885 |
| US-10781170-B1 | Process for preparing Brivaracetam | GABRA2, GABRA1, GABRB2 | BRD4 384/4885MAPT 737/4885MME 4225/4885 |
| US-20040204476-A1 | Oxopyrrolidine compounds, preparations of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2C19, CYP2C9, TPMT | BRD4 2416/4885MAPT 2184/4885MME 4119/4885 |
| US-20060258734-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of Levetiracetam and analogues | TPMT, CYP2C9, OTC | BRD4 1847/4885MAPT 1915/4885MME 4150/4885 |
| US-20070142647-A1 | Oxopyrrolidine compounds, preparation of said compounds and their use in the manufacturing of levetiracetam and analogues | CYP2D6, OTC, CYP2B6 | BRD4 1778/4885MAPT 2366/4885MME 3860/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.